Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. reported an insider equity grant to its Chief Commercial Officer, Adam H. Zaeske. On January 22, 2026, he received a stock option covering 56,900 shares of common stock at an exercise price of $36.76 per share, expiring on January 22, 2036.
The option vests 25% on January 22, 2027, with the remaining shares vesting quarterly until the fourth anniversary of the grant date, subject to continued service. On the same date, Zaeske was also granted 16,200 restricted stock units, which vest in four equal annual installments beginning January 22, 2027, each representing one share of common stock.
Harmony Biosciences Holdings, Inc. reported equity compensation and related share activity for President and CEO Jeffrey M. Dayno. On January 22, 2026, he received a stock option for 184,600 shares of common stock at an exercise price of $36.76, vesting 25% on January 22, 2027 and the rest quarterly until the fourth anniversary of the grant. He was also granted 52,900 restricted stock units (RSUs) that vest in four equal annual installments beginning January 22, 2027.
On January 24, 2026, 10,500 shares of common stock were issued upon vesting of previously granted RSUs, and 4,785 shares were withheld at $36.82 per share to satisfy tax obligations, leaving 5,715 shares held directly. On January 25, 2026, an additional 13,000 shares were issued from RSU vesting, with 5,654 shares withheld at $36.82 for taxes, leaving 7,346 shares held directly.
A holder has filed a notice to sell 3,746 shares of Harmony Biosciences common stock (HRMY). The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on or around 01/26/2026 on the NASDAQ market. These shares come from restricted stock units acquired from the issuer on 01/24/2026.
The notice also lists recent activity under a Rule 10b5-1 trading plan for Sandip Kapadia. Over the past three months, there were sales of 20,961 shares for $752,833.18 on 01/15/2026, 20,000 shares for $790,896.00 on 12/05/2025, and 3,427 shares for $119,945.00 on 11/21/2025. The filer represents that they are not aware of undisclosed material adverse information about Harmony Biosciences.
Harmony Biosciences Holdings, Inc. reported an insider sale by its chief financial officer, Sandip Kapadia. On January 15, 2026, Kapadia sold 20,961 shares of Harmony Biosciences common stock in an open-market transaction coded as a sale. The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to trade according to a preset schedule. The weighted average sale price was $35.9159 per share, with individual trades executed between $35.68 and $36.10. After this transaction, the Form 4 reports that Kapadia directly beneficially owned 0 shares of the company’s common stock.
An affiliate of HRMY has filed a Rule 144 notice to sell up to 20,961 shares of common stock, with an aggregate market value of 755,434.44. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/15/2026, and there were 57,596,358 shares of this class outstanding. The securities were acquired on 09/30/2025 as restricted stock units from the issuer.
Over the past three months, sales labeled as 10b5-1 sales for Sandip Kapadia included 20,000 common shares on 12/05/2025 for gross proceeds of 790,896.00 and 3,427 common shares on 11/21/2025 for gross proceeds of 119,945.00. The signer represents that they do not know any undisclosed material adverse information about the issuer’s current or prospective operations.
Harmony Biosciences Holdings, Inc. filed a current report describing a new press release with preliminary, unaudited net product revenue for the fourth quarter and full year ended December 31, 2025. The release also includes the company’s guidance for 2026 net product revenue and an update on its clinical programs.
The company will present at the 44th Annual JP Morgan Healthcare Conference on January 13, 2026, and the related presentation is attached to the report. The materials, including the press release and slideshow, are being furnished rather than filed, and the company highlights that they contain forward-looking statements subject to risks and uncertainties described in its prior SEC reports.
Harmony Biosciences Holdings, Inc. reported an insider transaction by its president, CEO and director on a Form 4. On 12/12/2025, the executive exercised a stock option for 20,000 shares of common stock at an exercise price of $8.22 per share, converting the option into shares.
That same day, the executive sold 20,000 shares and an additional 5,933 shares of common stock in open-market transactions under a Rule 10b5-1 trading plan. The reported weighted average sale price was $40.1073 per share, with individual trades occurring between $40.00 and $40.28. Following these transactions, the Form 4 reports 0 shares of common stock and 0 derivative securities beneficially owned directly from this option grant.
Harmony Biosciences Holdings, Inc. (HRMY) reported an insider stock sale by its chief financial officer. On 11/21/2025, the CFO sold 3,427 shares of common stock at a price of $35 per share, coded as an open market or similar sale (transaction code "S").
After this transaction, the reporting person disclosed beneficial ownership of 0 shares, held directly. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to predetermined instructions.
Harmony Biosciences (HRMY) reported strong Q3 2025 results. Net product revenue reached $239,455, generating gross profit of $179,805 and operating income of $65,487. Net income was $50,865, with diluted EPS of $0.87 on 58,717,910 weighted-average diluted shares.
R&D expense rose to $54,962 as the company advanced programs, while sales and marketing and G&A were $29,549 and $29,807, respectively. Cash and cash equivalents were $646,999, and total cash, cash equivalents and investments were $778,412 as of September 30, 2025. Long-term debt principal stood at $170,000 with a 2028 maturity schedule. The company triggered a $15,000 CVR payment tied to a Zynerba milestone, payable in Q4 2025. As of October 31, 2025, 57,596,358 common shares were outstanding. The ANDA settlements allow licensed generic entry beginning January 2030, or earlier under certain circumstances.
Harmony Biosciences (HRMY) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025 and posted an updated investor presentation. The materials are included as Exhibits 99.1 and 99.2 and are provided under Regulation FD.
The company states these exhibits are furnished and not deemed filed under Section 18 of the Exchange Act, and may be used in presentations to investors and analysts. Forward‑looking statements are subject to the risk factors described in prior SEC filings.